Ozer Baysal - Agenus Insider

  Executive
Mr. Ozer Baysal is Chief Commercial Officer, Head of HR of Agenus Inc. Mr. Baysal was Chief Business Officer since January 2013 until July 1, 2017. Prior to joining Agenus Mr. Baysal spent more than 30 years with Pfizer in a broad number of functional and geographic areas, most recently serving as President of Europe, Emerging Markets Region. While at Pfizer, he held key leadership positions in Marketing, Sales, and Manufacturing, and was actively involved with numerous licensing and MA activities
Age: 60  Executive Since 2017      
781-674-4400  http://agenusbio.com
Baysal holds a bachelor degree from Bosphorus University in Industrial Engineering and has completed the Programs for Leadership and Management Development at Harvard Business School.

Management Efficiency

The company has return on total asset (ROA) of (50.0) % which means that it has lost $50.0 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (421.01) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.74 M in liabilities. Agenus has Current Ratio of 1.29 suggesting that it is in a questionable position to pay out its financial obligations when they are due.

Similar Executives

Found 8 records

EXECUTIVE Since

Albert MarchioEdge Therapeutics
2017
Albert IIEdge Therapeutics
N/A
Sonja NelsonNantKwest
2018
Gregory GinEdge Therapeutics
2018
Herbert DOEdge Therapeutics
N/A
Herbert FaleckEdge Therapeutics
2013
Beth TaylorEndocyte
2016
Alison ArmourEndocyte
2015

Entity Summary

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the bodys immune system to fight cancer. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 255 people.Agenus (AGEN) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 255 people. Agenus is listed under Pharmaceutical Products category by Fama And French industry classification.

Agenus Leadership Team

Robert Stein, Chief Scientific Officer
James Gorman, Vice President - Strategic Planning and Portfolio Management
Ozer Baysal, Chief Bus. Officer
Christian Cortis, Chief Strategy Officer and Head of Finance
Ulf Wiinberg, Director
Shalini Sharp, Director
Alexander Duncan, CTO and Head - Research
Wadih Jordan, Independent Director
Christine Klaskin, Principal Accounting Officer and VP of Fin.
Garo Armen, Founder, Executive Chairman, CEO and Chairman of Bus. and Devel. Advisory Committee
JeanMarie Cuillerot, Chief Medical Officer
Brian Corvese, Independent Director
Karen Valentine, Chief Compliance Officer, VP, General Counsel and Secretary
Shahzad Malik, Independent Director
Evan Ballantyne, CFO
Timothy Wright, Lead Independent Director
Evan Kearns, Vice President General Counsel, Secretary

Stock Performance Indicators

Current Sentiment - AGEN

Agenus Investor Sentiment

Most of Macroaxis users are presently bullish on Agenus. What is your sentiment towards investing in Agenus? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Agenus Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Agenus and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Search macroaxis.com